---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-331244"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2025-12-29T23:59:59+00:00"
generated_at: "2026-05-16T12:04:54.908061+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio expands ATM equity offering capacity by $460M; authorized shares increased by 300M

## Summary
- Amendment to ATM agreement with Jefferies LLC authorizes up to $459.97M in additional common stock sales.
- Board and stockholders approved increase in authorized common shares from 1.35B to 1.65B, effective Nov 10, 2025.
- ATM sales will be made under existing S-3ASR shelf registration and prospectus supplement dated Dec 23, 2025.
- Amendment also updates settlement to T+1 and modifies auditor comfort letter delivery requirements.

## SEC filing metadata
- accession: 0001193125-25-331244
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2025-12-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/0001193125-25-331244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/d61833d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-331244
- JSON: https://secwatch.observer/filing/0001193125-25-331244.json
- Plain text: https://secwatch.observer/filing/0001193125-25-331244.txt

## Key facts
- Material Agreements
  ImmunityBio, Inc. amended Amendment No. 1 with Jefferies LLC valued at $459,972,480 (effective 2025-12-23).
  - Action: amendment
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: $459,972,480
  - Effective: 2025-12-23
  source text: On December 23, 2025, ImmunityBio, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment to Sale Agreement”) to the Open Market Sale Agreement SM dated April 30, 2021, (the “Sale Agreement”) with Jefferies LLC (the “Agent”) relating to the sale and issuance of shares of its common stock, par value $0.0001 per share (the “Shares”), from time to time through an “at the market” offering program under which the Agent acts as the Company’s sales agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/0001193125-25-331244-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.